The Michael J. Fox Foundation for Parkinson's Research has awarded a total of $1.9 million in grants to develop neuroimaging techniques for visualizing the clumping of the alpha-synuclein protein in the living human brain.
The program was funded with a lead gift from the Edmond J. Safra Foundation and will provide grants to six teams, according to the Michael J. Fox Foundation in New York City:
- Development and Screening of Contrast Agents for In Vivo Imaging of Parkinson's Disease: Brian Bacskai, Ph.D., and Pamela McLean, Ph.D., of Massachusetts General Hospital in Boston
- Utility of the Amyloid Ligand [18F] FDDNP in Human PET Imaging in Parkinson's Disease: Dr. Yvette Bordelon, Ph.D., of the University of California, Los Angeles
- 18F-labeled Alpha-Synuclein Ligands for PET Imaging of Lewy Bodies: Franz Hefti, Ph.D., of Avid Radiopharmaceuticals in Philadelphia, and Alan Snow, Ph.D., of ProteoTech in Seattle
- Generation of Alpha-Synuclein Conformation-specific Aptamers for In Vivo Bioimaging of Alpha-Synuclein Pathology: Dr. Poul Henning Jensen, Ph.D., of the University of Aarhus in Denmark
- A Strategy to Develop a Radiotracer Targeting Alpha-Synuclein: Dr. Kenneth Marek of the Institute for Neurodegenerative Disorders in New Haven, CT, and Omar El-Agnaf, Ph.D., of the United Arab Emirates University in Al Ain
- In Vivo SPECT Imaging of Synuclein Aggregation with Morphology-specific Antibody-based Ligands: Michael Sierks, Ph.D., of Arizona State University in Tempe
Related Reading
Gene therapy for Parkinson's disease modulates abnormal brain networks, November 20, 2007
Gene therapy treatment offers Parkinson's relief, June 25, 2007
Copyright © 2009 AuntMinnie.com
